[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625898":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":35,"responsibleParty":99,"collaborators":30,"id":101,"slug":30,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":102,"sex":108,"minAge":109,"maxAge":30,"enrollmentInfo":110,"targetDuration":30,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":38,"whyStopped":30,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},{"fullName":5,"class":6},"Exelixis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Zanzalintinib","EXPERIMENTAL","Participants will receive zanzalintinib once daily (QD).",[13],"Drug: Zanzalintinib",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Administered as specified in the treatment arm.",[9],[20],"XL092",[22],{"name":23,"affiliation":5,"role":24},"Study Director","STUDY_DIRECTOR",[26,32],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Exelixis Clinical Trials","CONTACT","1-888-EXELIXIS (888-393-5494)",null,"druginfo@exelixis.com",{"name":33,"role":28,"phone":34,"phoneExt":30,"email":30},"Backup or International","650-837-7400",[36,50,60,70,79,89],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":30},"Baptist Health Miami Cancer Institute","RECRUITING","Miami","Florida","33176","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-80.19366,25.77427,{"lat":48,"lon":47},{"facility":51,"status":38,"city":52,"state":53,"zip":54,"country":42,"countryCode":43,"cosmosGeoPoint":55,"geoPoint":59,"contacts":30},"Washington University School of Medicine","Bay Saint Louis","Mississippi","63110",{"type":45,"coordinates":56},[57,58],-89.33005,30.30881,{"lat":58,"lon":57},{"facility":61,"status":38,"city":62,"state":63,"zip":64,"country":42,"countryCode":43,"cosmosGeoPoint":65,"geoPoint":69,"contacts":30},"UT MD Anderson Cancer Center","Houston","Texas","77030",{"type":45,"coordinates":66},[67,68],-95.36327,29.76328,{"lat":68,"lon":67},{"facility":71,"status":38,"city":72,"state":63,"zip":73,"country":42,"countryCode":43,"cosmosGeoPoint":74,"geoPoint":78,"contacts":30},"UT Health San Antonio Mays Cancer Center","San Antonio","78229",{"type":45,"coordinates":75},[76,77],-98.49363,29.42412,{"lat":77,"lon":76},{"facility":80,"status":38,"city":81,"state":82,"zip":83,"country":42,"countryCode":43,"cosmosGeoPoint":84,"geoPoint":88,"contacts":30},"Inova Center for Personalized Health","Fairfax","Virginia","22031",{"type":45,"coordinates":85},[86,87],-77.30637,38.84622,{"lat":87,"lon":86},{"facility":90,"status":38,"city":91,"state":92,"zip":93,"country":42,"countryCode":43,"cosmosGeoPoint":94,"geoPoint":98,"contacts":30},"UW Carbone Cancer Center","Madison","Wisconsin","53792",{"type":45,"coordinates":95},[96,97],-89.40123,43.07305,{"lat":97,"lon":96},{"type":100,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100625898",false,"NCT07428616","A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma","A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma","STELLAR-201","Key Inclusion Criteria:\n\n* Histologically confirmed World Health Organization (WHO) grade 1, 2, or 3 meningioma.\n* Developed recurrent disease or progressive disease (PD) after receiving standard therapy (for example, surgery and\u002For radiation) or have been deemed ineligible to receive these therapies. At least 1 prior course of meningioma-directed radiotherapy is required, if not contraindicated.\n* Radiologically documented progression of any existing tumor (growth \\> 15% of the bidimensional enhancing tumor within the prior 6 months or appearance of new lesions (including intra and extracranial manifestations).\n* For participants treated with external beam radiation, interstitial brachytherapy, or radiosurgery, an interval ≥ 24 weeks must have elapsed from completion of therapy to initiation of treatment.\n* Measurable disease by RANO meningioma criteria as determined by the investigator, obtained ≤ 14 days prior to initiation of treatment.\n* Karnofsky performance status (KPS) ≥ 60%.\n* Demonstrate adequate organ and marrow function within 14 days of treatment initiation\n\nKey Exclusion Criteria:\n\n* Prior history of hypertensive encephalopathy at any time.\n* Extracranial lesions invading major blood vessels including, but not limited to, inferior vena cava, pulmonary artery, or aorta.\n* Contraindication to magnetic resonance imaging (MRI).\n* Local therapy (surgery and\u002For radiation therapy) is indicated per investigator\n* Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks or 5 half-lives, whichever is shorter, before initiation of treatment. There is no limit on prior systemic therapies\n* Prior Surgery - completed wound healing must occur prior to initiation of treatment; ≥ 8 weeks for major surgery, ≥ 7 days for minor surgery, including stereotactic biopsies.\n* The participant has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n  * Cardiovascular disorders, including uncontrolled hypertension,\n  * Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation,\n  * Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 milliliters \\[mL\\]) of red blood within 12 weeks before initiation of treatment or other history of significant bleeding (eg, intracranial hemorrhage\u002Fbleeding), or\n  * Other clinically significant disorders.\n* Requirement for hemodialysis or peritoneal dialysis.\n* History of solid organ or allogeneic stem cell transplant.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":111,"type":112},100,"ESTIMATED","INTERVENTIONAL",[115],"PHASE2","The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.",[118],"Meningioma",[118,120,121,122,123,124,9,20,125,126,127,128,129],"Recurrent Meningioma","Progressive Meningioma","Atypical Meningioma","Anaplastic Meningioma","Brain","Grade 1 Meningioma","Grade 2 Meningioma","Grade 3 Meningioma","Intracranial Neoplasms","Extracranial Meningioma","2026-06-19",{"date":132,"type":133},"2026-06-24","ACTUAL",{"date":135,"type":133},"2026-05-21",{"date":137,"type":112},"2029-09-30",{"name":5,"class":6},6]